Barbu, Dominique Rainteau, Harry Sokol, Chantal Housset 6:00 PM 102: Intrahepatic bile duct regeneration
in mice does not require HNF6 and RBP-J-mediated Notch signaling selleck chemical Teagan J. Walter, Charles Vanderpool, Mary Kay Washington, Anna L. Means, Stacey S. Huppert SIG Program Sunday, November 3 4:45 – 6:45 PM Room 145 Challenges in Diagnosis and Management of Chronic Hepatitis B Virus (HBV) Infection in Endemic Countries Sponsored by the Hepatitis B SIG MODERATORS: Jordan J. Feld, MD Brian J. McMahon, MD This program will discuss the status of current programs for diagnosis and management of chronic HBV in developing countries endemic for HBV and what the challenges are. Learning Objectives: Define what we know and what gaps remain in our understanding of the epidemiology of chronic hepatitis B and Hepatocellular Carcinoma (HCC) in developing countries Discuss current existing programs for diagnosis and management of HBV in different regions of the world Identify challenges that need to be overcome to provide care for persons with chronic HBV Describe the components
of a specific action plan for management of HBV in resource-constrained regions 4:45 – 4:55 PM Introduction Brian J. McMahon, MD and Jordan J. Feld, MD 4:55 – 5:10 PM Epidemiology of HBV and Hepatocellular Carcinoma (HCC): Strategies to Collect the Needed Data John W. Ward, MD 5:10 – 5:25 PM Access to Treatment: p38 MAPK inhibitor Asia Seng Gee Lim, MD 5:25 – 5:40 PM Access to Treatment: Africa Mark R. Thursz, MD 5:40 – 5:55 PM WHO Plan for Management of Chronic HBV Stefan Wiktor, MD 5:55 – 6:10 PM Lessons from HIV David Thomas, MD 6:10 – 6:40 PM Panel Discussion 6:40 – 6:45 PM Conclusion SIG Program Sunday, Farnesyltransferase November 3 4:45 – 6:45 PM Room 147 The Changing Spectrum of Bacterial Infections in Cirrhosis Sponsored by the Acute in Chronic Liver Failure SIG MODERATORS: Jasmohan S. Bajaj, MD Patrick S. Kamath, MD The overarching purpose
of this program is to provide a cutting- edge and detailed understanding of recent advances and research into the impact of the changing spectrum of infections in cirrhosis. There is an immense interest in the management and prevention of infections, especially nosocomial and MDR-organism-related infections. This is evidenced by the recent publications and controversies regarding gut microbiome, continuing prophylaxis and changing strategies for management of infections in inpatient and outpatient cirrhotics. This program is distinctive because it incorporates clinical and translational science that will engender a keen debate about both clinical and research issues. Learning Objectives: Measure the impact of the changing bacteriology of infections in cirrhosis Report the advances in the pathogenesis of infections Investigate the measures to prevent infectious disease 4:45 – 4:50 PM Introduction Jasmohan S.